Autism is known as a “spectrum” disorder because there is wide variation in symptoms, skills and levels of impact people experience.
The estimated UK prevalence of ASD is 1% and because of its early onset, lifelong persistence, and high levels of associated impairment, it is recognised as a major public health concern.
Flynn Pharma is committed to the delivery of high quality medical educational events that support the continued development of healthcare professionals - it's our way of helping you to help your patients.
Don't miss out. Over the course of 2021 Flynn will host a series of educational events and webinars around ASD and other neurodevelopmental disorders that are free for healthcare professionals to attend. Sign up to receive our latest updates.
Become an NDD Community Member
Join our community as a Member and keep up to date on the latest developments.
Slenyto® Treatment Goals and Therapy Optimisation – A Guide for Healthcare Professionals
Insomnia in children with ASD is perceived to be one of the most challenging health effects of autism and a successful intervention needs to define realistic and agreed outcomes that can be systematically monitored. This simple guide ...
Slenyto® Therapeutic Bulletin
A succinct summary of the evidence-base for Slenyto® (paediatric prolonged-release melatonin) for the treatment of insomnia in children and adolescents with Autistic Spectrum Disorder ...
ADHD and ASD
Information for parents of children who may have characteristics or symptoms suggestive of ADHD and/or ASD.
References:1. Diagnostic and Statistical Manual of Mental Disorders, 5th edition: DSM-5. American Psychiatric Association, 201
2. NICE Clinical guideline CG170 Autism spectrum disorder in under 19s: support and management. Published August 2013